Cambridge Healthtech Institute’s 5th Annual

Combination Immunotherapy

Targeting Immunotherapy Combinations for Increased Clinical Efficacy

11-12 March 2020

 

Treating patients with an immunotherapy combination has become commonplace for many cancers. With an abundance of combinations to choose from and plenty more clinical trials ongoing, it is difficult to know which combinations will be most effective. Whether double immunotherapy combinations or immune checkpoint inhibitors combined with conventional cancer therapy, there are numerous factors that may influence therapeutic success, with varying degrees of supporting evidence. Predictive biomarkers, neoantigens, therapeutic mechanism, reducing toxicity and the immune response are all important considerations. Join us for the 5th Annual Combination Immunotherapy conference and target immunotherapy combinations for increased clinical efficacy.

Preliminary Agenda

OPENING KEYNOTE

KEYNOTE PRESENTATION: PD-1 Antibodies Are Transforming Cancer Treatment

Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharpe & Dohme

BISPECIFIC ANTIBODY AND CHECKPOINT INHIBITOR COMBINATIONS

A Novel Class of Fully Human Costimulatory Bispecific Antibodies for Cancer Immunotherapy

Dimitris Skokos, PhD, Associate Director, Immunology & Inflammation, Regeneron Pharmaceuticals

TARGETING THE TUMOUR MICROENVIRONMENT

Principles Determining the Selection of Combinatorial Therapies in Immune Oncology

Franco Marincola, PhD, Chief Scientific Officer, Refuge Biotechnologies

Neoadjuvant Immunotherapy for Melanoma

Tina J. Hieken, MD, FACS, Associate Professor, Surgery, Mayo Clinic

Developing Personalized Neoantigen Cancer Vaccines to Target Solid Tumors

Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody AS

NEXT GENERATION IO COMBINATIONS

Combining Immunotherapy with DNA-Damage Repair Agents: Scientific and Clinical Rationale, Current Status, and Future Prospects

Ivan Diaz Padilla, MD, Executive Medical Director, Oncology, Merck KGaA

Antibody-Drug Conjugate- and Oncolytic Virus-Based IO Combinations: Different Modalities - Common Themes

Philipp Mueller, PhD, Senior Principal Scientist Research and Development, Boehringer Ingelheim

Immunotherapy with avb6 Integrin-Targeted CAR T-Cells, Directed by CXCR2-Specific Chemokines

John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London




For more details on the conference, please contact:
Joel Hornby, BSc Hons

Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-1816
Email: jhornby@healthtech.com

 

For partnering and sponsorship information, please contact:

Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com

 

 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag